Madhu Gowda, MD
Pulmonary Disease · Seymour, CTNPI 1104856921
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $13,600 of the $21,379 with a category attached, or 63.6%. AstraZeneca accounts for 77.8% of it on its own, with 23 other manufacturers making up the rest. Among pulmonary disease clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 153 payments — averaging $139.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$17K
- Boehringer Ingelheim$2K
- GSK$1K
- Lilly USA, LLC$496
- Novo Nordisk$288
- Johnson & Johnson$242
- plus $971 from 18 others
What the payments were for
- Speaking & faculty fees$13,60064%
- Travel & lodging$870%
- Food & beverage$7,59236%
- Education$990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 41 | $16,622 |
| Boehringer Ingelheim | 16 | $1,645 |
| GSK | 52 | $1,114 |
| Lilly USA, LLC | 4 | $496 |
| Novo Nordisk | 5 | $288 |
| Johnson & Johnson | 3 | $242 |
| Amgen | 2 | $139 |
| Idorsia Pharmaceuticals US Inc | 1 | $122 |
| Verona Pharma, Inc. | 6 | $109 |
| Merck | 1 | $100 |
| Sanofi-aventis U.S. LLC | 1 | $99 |
| Bayer | 3 | $77 |
| Haemonetics Corporation | 1 | $69 |
| Sunovion Pharmaceuticals Inc. | 6 | $66 |
| CSL Behring | 2 | $38 |
| Phathom Pharmaceuticals, Inc. | 1 | $27 |
| Abbott | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Insmed, Inc. | 1 | $16 |
| Phadia US Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
| Pfizer | 1 | $14 |
| AbbVie | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$14,085
- JARDIANCE$1,841
- FARXIGA$1,312
- BREZTRI$730
- TRELEGY ELLIPTA$249
- RYBELSUS$231
- XARELTO$125
- QUVIVIQ$122
- Otezla$122
- BREZTRI AEROSPHERE$110
How this compares
$21,379 in reported general payments places this provider in the 90th percentile of 255 pulmonary disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 246 | $276,280 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 291 | $261,841 |
| EliquisApixaban | 204 | $176,145 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 196 | $153,243 |
| MounjaroTirzepatide | 111 | $134,527 |
| FarxigaDapagliflozin Propanediol | 112 | $127,845 |
| Spiriva HandihalerTiotropium Bromide | 116 | $91,586 |
| XareltoRivaroxaban | 69 | $76,125 |
| Incruse ElliptaUmeclidinium Bromide | 163 | $69,751 |
| OzempicSemaglutide | 52 | $64,457 |
| NucalaMepolizumab | 12 | $51,378 |
| Spiriva RespimatTiotropium Bromide | 70 | $47,310 |
| Breo ElliptaFluticasone/Vilanterol | 86 | $45,645 |
| Pirfenidone | 15 | $40,403 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 61 | $37,875 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Incruse Ellipta, Nucala, Breo Ellipta, Anoro Ellipta | $1,114 | $474,093633 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat | $1,645 | $332,668335 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $16,622 | $293,133357 claims |
| PfizerEliquis | $14 | $176,145204 claims |
| Lilly USA, LLCMounjaro, Trulicity | $496 | $153,207124 claims |
| Johnson & JohnsonXarelto | $242 | $76,12569 claims |
| Novo NordiskOzempic | $288 | $64,45752 claims |
| MerckDulera | $100 | $4,55514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 255 pulmonary disease providers in Connecticut.
Other pulmonary disease in Seymour
- Geoffrey ChuppNew Haven$1.2M
- Tapas BandyopadhyayWest Hartford$483K
- Raj ParikhHartford$386K
- Patrick TroyHartford$385K
- Michael ImevboreNew Haven$323K
- Jeffrey NascimentoHartford$213K
- Thinesh DahanayakeNorwich$192K
- Naftali KaminskiNew Haven$180K
- Daniel GerardiHartford$156K
- Roman SpivakAnsonia$140K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.